marimastat


Also found in: Wikipedia.

marimastat

A matrix metalloproteinase and angiogenesis inhibitor which had shown early promise for managing advanced malignancy; phase-III studies failed in this expectation, however. Marimastat may have a secondary role as maintenance therapy for advanced colorectal, ovarian, pancreas, prostate and other cancers.
 
Adverse effects
Musculoskeletal pain.

marimastat

Oncology An angiogenesis inhibitor and matrix metalloproteinase inhibitor in clinical trials as an ancillary therapy for advanced malignancy–ovary, pancreas, small cell of lung, stomach, glioblastoma. See Angiogenesis inhibitors.
References in periodicals archive ?
The three new kits are the Marimastat caproKit, SAHA caproKit and GDP caproKit, respectively and increase the number of commercially available caproKits to a total of seven.
British Biotech was humbled in the late 1990s when its leading drug hope, a cancer treatment called Marimastat, failed clinical trials.
A recent trial evaluating the combination of marimastat (a protease inhibitor) and temozolomide reported a 6-month progression-free survival of 39% compared to 21% with temozolomide alone (Groves et al.
Once one of the bright lights of the UK sector, it was hit by the failure of cancer drug Marimastat and pancreatitis treatment Zacutex, both at one point hailed as potential blockbusters.
British Biotech, once the flagship of the UK biotechnology industry, has been looking at new products after the failure of cancer drug Marimastat.
But now it seems the treatment, Marimastat, is effective.
This trial was designed to study the effect of marimastat compared to placebo in prolonging survival of patients with glioblastoma, a form of brain cancer.
Overall, the company's work force has reduced by 32 per cent during the year to 311 staff and is planned to fall further to 280 as current marimastat clinical trials are completed.
BELEAGUERED biotechnology group British Biotech said yesterday their cancer drug Marimastat had failed early tests.
Currently, Marimastat, an MMPI made by British Biotech Pharmaceuticals, Ltd.
Then head of research, Dr Andrew Millar, was sacked in April after accusing directors of over-optimistic statements on experimental drugs Zacutex and Marimastat.
Since the early failure of drugs such as Avastin, Erbitux, SU5416, Marimastat, Endostatin and Angiostatin, new clinical trials have commenced that will define whether the anti-angiogenetic and vascular targeting strategies will hold.